Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solifenacin suspension in pediatric neurogenic detrusor overactivity (Phase 3)
2011-000330-11Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of solifenacin in detrusor hyperreflexia (DH), sponsored by Astellas Pharma. Primary endpoint: Change in maximum cystometric capacity (MCC). Started Jan 2012; status: completed.
02
Drugs
solifenacin
03
Conditions
detrusor hyperreflexia (DH)
Beyond the preview
Go deeper on 2011-000330-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000330-11.